On 30 March 2023, the Supreme Court of Canada dismissed Pharmascience's application for leave to appeal(1) a decision of the Federal Court of Appeal upholding the validity of two patents relating to apixaban (Bristol-Myers Squibb's Eliquis). The Federal Court of Appeal had dismissed Pharmascience's appeal of a Federal Court decision upholding the validity of:

  • Canadian Patent No. 2,461,202 (apixaban and uses thereof in the treatment of thromboembolic disorders); and
  • Canadian Patent No. 2,791,171 (tablet formulations of apixaban).

For further details please see "Federal Court of Appeal upholds validity of two patents relating to Eliquis".

For further information on this topic please contact Malcolm Harvey at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smartbiggar.ca.


(1) Docket No. 40400.